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Abstract
Background: Anti-NMDA-receptor encephalitis is an immune-mediated inflammatory disorder of the central
nervous system. Brain MRI is unremarkable in at least 50 % of patients and highly variable in the remaining patients
with signal abnormalities in different brain regions. Only scarce reports exist on other imaging modalities.
Case presentation: A 31-year-old woman sub-acutely developed psychosis, behavioural changes, amnesia,
alternating states of agitation and mutism, fever and epileptic seizures. Clinically suspected diagnosis of anti-
NMDA-receptor encephalitis was confirmed by the detection of anti-NMDA receptor antibodies in CSF and
serum. During the acute phase, brain MRI abnormalities were found in both insular cortices and hippocampi,
whereas F18-FDG-PET showed hypermetabolism bilaterally in insular and prefrontal cortex. After resection of the
underlying ovarian teratoma and with multimodal immunotherapy the patient substantially improved reaching
a modified Rankin Scale score of 2 after 3 months. At follow-up, both hippocampi were still affected on MRI,
whereas insular cortex appeared normal; however, both regions showed prominent glucose hypometabolism.
Conclusions: Here, we report bi-insular cortical abnormalities on MRI and F18-FDG-PET in a patient with anti-
NMDA-receptor encephalitis during the acute phase and after clinical improvement.
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Background
Anti-N-methyl-D-aspartate-receptor (NMDAR) encephal-
itis is an immune-mediated inflammatory disorder of the
central nervous system first described in 2007 [1]. Patients
usually present with a clinical syndrome including psych-
osis, behavioural changes, amnesia and epileptic seizures,
frequently followed by dyskinesia and decreased levels of
consciousness [2]. The disease has a female predominance
and is associated with an underlying tumour, mostly ovar-
ian teratoma, in approximately 50 % of cases [2]. Patients
are treated with tumour resection if applicable and im-
munotherapy (corticosteroids, intravenous immunoglobu-
lins and/ or plasma exchange, and in case of treatment
failure cyclophosphamide and/ or rituximab) [3]. About
75 % of patients fully recover or show mild disability, the
remaining patients suffer from severe disability or die. The
main predictor of good outcome is the early initiation of
treatment [3].
Diagnosis is obtained by the detection of anti-
NMDAR antibodies in cerebrospinal fluid (CSF) and/
or serum [4]. Besides that, diagnostic work-up includes
further examinations such as routine CSF analysis,
tumour screening and brain imaging [2]. Brain MRI is
unremarkable in 50–90 % of patients [2, 3, 5]; in the
remaining patients abnormalities are highly variable
evolving in the white and grey matter [6]. White matter
lesions have been reported in the medial temporal,
frontal, parietal, occipital lobe [1, 4, 5, 7, 8], cingulate
gyrus [9, 10] and corpus callosum [4], whereas grey
matter has been shown to be involved in cerebral cor-
tex [1, 4, 9] and certain nuclei such as thalamus [11] or
basal ganglia [4, 12]. In addition, affections of the cere-
bellum [4, 9, 13] and brainstem [4, 9] have been ob-
served. MRI alterations are typically subtle despite the
severity and duration of signs and symptoms [2].
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Only scarce evidence exists on other imaging modal-
ities. F18-FDG-PET can reveal pathological changes even
when MRI is normal [6]. Glucose hypermetabolism has
been found in frontotemporal areas [5, 8–10, 14], in the
cerebellum [5, 8, 9], brainstem [9], thalamus and basal
ganglia [8].
In the following, we present a case of anti-NMDAR
encephalitis with bi-insular cortical abnormalities on
MRI and F18-FDG-PET during the acute phase of the
disease and after substantial clinical improvement.
Case presentation
A 31-year-old woman presented at the hospital’s emer-
gency department with prominent, sub-acutely evolv-
ing psychiatric signs and symptoms including bizarre
behaviour, delusional thoughts and alternating states
of agitation and mutism. Besides that, she showed
short-term amnesia, fever and complex epileptic sei-
zures. Her family reported that she had already com-
plained about insomnia and general discomfort for the
past 2 weeks; otherwise there was no history of any
diseases and no use of concomitant medication. The
neurological examination revealed no further abnor-
malities, especially no meningism and no focal
deficits.
Emergency brain MRI showed diffusion-restriction on
diffusion-weighted images in insular cortex, and hyper-
intensity on fluid-attenuated inversion recovery
(FLAIR) and T2-weighted images in insular cortex and
hippocampus (Fig. 1a). F18-FDG-PET showed hyperme-
tabolism in insular and prefrontal cortex (Fig. 2a). CSF
analysis revealed a mild pleocytosis comprising mono-
nuclear cells. Diagnosis was made by the detection of
anti-NMDAR antibodies in CSF and serum. Tumour
screening by whole body imaging revealed a tumour of
the right ovary that was subsequently resected and
histopathologically proven to be a teratoma.
After tumour resection and multimodal immunotherapy
(plasmapheresis for 4 days followed by intravenously ap-
plied corticosteroids over 5 days at a total dose of 4 g) the
patient improved substantially. In serum samples, anti-
NMDAR antibody titres decreased from 1:160 to 1:20 [15].
After 3 months the patient still had slight disability, was
able to look after her own affairs without assistance, but
was unable to carry out all previous activities, mainly due
to memory deficits (corresponding to a modified Rankin
Scale score of 2). At this point of time insular abnormalities
on diffusion- and T2/ FLAIR-weighted MRI had disap-
peared, whereas hippocampal FLAIR/ T2-hyperintensity
remained (Fig. 1b). In both areas prominent glucose hypo-
metabolism was observed; glucose-metabolism in prefontal
cortex was normal (Fig. 2b).
Conclusions
Here, we report bi-insular cortical involvement in
anti-NMDA-receptor encephalitis [6] as shown by
structural and metabolic abnormalities. The striking
correlation between initial MRI findings (T2/ FLAIR
hyperintensity and diffusion-restriction, respectively)
and initial F18-FDG-PET hypermetabolism that was
followed by a prominent hypometabolism suggests
that structural disruption and not only functional
Fig. 1 Insular and hippocampal MRI abnormalities. a MRI during acute phase of the disease (2 weeks after onset) shows diffusion restriction on
diffusion-weighted images (DWI), hyperintensity on fluid-attenuated inversion recovery (FLAIR) images bilaterally, right-accentuated in the insular
cortex as well as slight hyperintensity on T2-weighted and FLAIR images in both hippocampi. b After 3 months with substantial clinical improvement
bi-insular diffusion restriction and FLAIR abnormalities have disappeared; hippocampal T2/ FLAIR hyperintensities are still visible
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changes in brain metabolism results in medium-term
brain dysfunction [16].
There are some considerations with regard to differ-
ent, longitudinally performed imaging modalities in
patients with anti-NMDAR encephalitis. In general,
imaging abnormalities reflect a present disruption
within brain areas, which might improve [16] or even
disappear with clinical improvement, as this was the
case in our patient. However, it has to be highlighted
that a significant proportion of patients shows normal
routine MRI during the acute phase of the disease and
that structural changes might only be detected by
more sophisticated MRI methods such as volumetry,
analysis of microstructural integrity or resting state
functional connectivity [17, 18]. Timing of imaging is
another crucial issue. Whereas MRI abnormalities
might resolve over time, hypermetabolic areas on F18-
FDG-PET during the acute phase of the disease typic-
ally turn into hypometabolic state during the early re-
covery phase. During this time, patients have already
clinically improved but are still disabled, as this was
also the case in our patient. After a longer follow-up
glucose hypometabolism might be alleviated and ac-
companied by further clinical improvement [19].
In conclusion, this case confirms that there exists a
serial changing brain pattern on MRI and F18-FDG-PET
and depicts involvement of insular cortex in patients
with anti-NMDA-receptor encephalitis.
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Fig. 2 Evolution of glucose metabolism over time. a F18-FDG-PET during acute phase of disease (2 weeks after onset) shows bi-insular and bi-frontal
glucose hypermetabolism as well as glucose hypometabolism occipital and partially in the parietal lobe. b After 3 months there is a marked bi-insular
and bi-hippocampal hypometabolism, whereas prefrontal, occipital and parietal glucose-uptake is normal. F18-FDG-PET scans have been co-registered
with MRI in order to correlate metabolic pathologies with anatomical structures
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